Wednesday , October 18 2017
Home / Therapies / DPP-4 Therapy Center (page 3)

DPP-4 Therapy Center

TECOS Trial: No CVD Risks or Heart Failure with Sitagliptin in High-Risk Diabetic Patients

No significant difference in incidence of infections, cancer, renal failure, or severe hypoglycemia… In patients with type 2 diabetes and cardiovascular disease, the use of sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used to lower HbA1c levels, is not associated with an increased risk of cardiovascular events, according to ...

Read More »